Clínica Baviera, S.A. operates a network of ophthalmological clinics. More Details
No risks detected for CBAV from our risk checks.
Excellent balance sheet and good value.
Share Price & News
How has Clínica Baviera's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBAV is not significantly more volatile than the rest of Spanish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CBAV's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CBAV underperformed the Spanish Healthcare industry which returned -6.5% over the past year.
Return vs Market: CBAV underperformed the Spanish Market which returned -8.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Clínica Baviera's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StClínica Baviera (BME:CBAV) Has A Pretty Healthy Balance Sheet
4 weeks ago | Simply Wall StIs Weakness In Clínica Baviera, S.A. (BME:CBAV) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
1 month ago | Simply Wall StClínica Baviera (BME:CBAV) Has Compensated Shareholders With A Respectable 72% Return On Their Investment
Is Clínica Baviera undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CBAV (€10.3) is trading below our estimate of fair value (€22.12)
Significantly Below Fair Value: CBAV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CBAV is good value based on its PE Ratio (19.2x) compared to the XE Healthcare industry average (26x).
PE vs Market: CBAV is good value based on its PE Ratio (19.2x) compared to the Spanish market (22.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CBAV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CBAV is overvalued based on its PB Ratio (5x) compared to the XE Healthcare industry average (1.9x).
How is Clínica Baviera forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Clínica Baviera has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Clínica Baviera is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Clínica Baviera competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Clínica Baviera performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBAV has high quality earnings.
Growing Profit Margin: CBAV's current net profit margins (10.1%) are lower than last year (10.4%).
Past Earnings Growth Analysis
Earnings Trend: CBAV's earnings have grown by 14.3% per year over the past 5 years.
Accelerating Growth: CBAV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CBAV had negative earnings growth (-4.2%) over the past year, making it difficult to compare to the Healthcare industry average (-0.3%).
Return on Equity
High ROE: CBAV's Return on Equity (31.1%) is considered high.
How is Clínica Baviera's financial position?
Financial Position Analysis
Short Term Liabilities: CBAV's short term assets (€26.8M) exceed its short term liabilities (€18.6M).
Long Term Liabilities: CBAV's short term assets (€26.8M) do not cover its long term liabilities (€56.5M).
Debt to Equity History and Analysis
Debt Level: CBAV's debt to equity ratio (27.1%) is considered satisfactory.
Reducing Debt: CBAV's debt to equity ratio has reduced from 80.3% to 27.1% over the past 5 years.
Debt Coverage: CBAV's debt is well covered by operating cash flow (260.1%).
Interest Coverage: CBAV's interest payments on its debt are well covered by EBIT (31.2x coverage).
What is Clínica Baviera current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBAV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBAV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBAV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBAV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CBAV is not paying a notable dividend for the Spanish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBAV's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Eduardo Baviera Sabater (52 yo)
Mr. Eduardo Baviera Sabater serves as the Chief Executive Officer of Clínica Baviera, S.A. and served as its Executive Chairman since February 12 2007 and also served as its Managing Director. Mr. Baviera ...
CEO Compensation Analysis
Compensation vs Market: Eduardo's total compensation ($USD0.00) is below average for companies of similar size in the Spanish market ($USD541.26K).
Compensation vs Earnings: Eduardo's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||no data||€200.00k||no data|
|Secretary & Independent Director||12.42yrs||€33.20k||0.00031% |
|Independent Director||1.58yrs||no data||no data|
|Chairman||3.33yrs||no data||no data|
|Director||3.33yrs||no data||no data|
|Director||3.33yrs||no data||no data|
|Director||3.33yrs||no data||no data|
Experienced Board: CBAV's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Clínica Baviera, S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Clínica Baviera, S.A.
- Ticker: CBAV
- Exchange: BME
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: €166.289m
- Shares outstanding: 16.30m
- Website: https://www.clinicabaviera.com
Number of Employees
- Clínica Baviera, S.A.
- Paseo de la Castellana nº 20
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CBAV||BME (Bolsas y Mercados Espanoles)||Yes||Common Shares||ES||EUR||Apr 2007|
|D9Z||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 2007|
|0GWJ||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Apr 2007|
|CBAVE||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Apr 2007|
Clínica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company’s clinics offers...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/04 19:45|
|End of Day Share Price||2020/12/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.